Atrix Laboratories Inc announced the appointment of Lloyd G. Glenn, vice president of marketing and corporate development. Glenn's duties include working with Atrix's marketing partners and distributors for the sale of Eligard (leuprolide acetate for injectable suspension), Atridox (8.5% doxycycline) and generic products.

David R. Bethune, Atrix's chairman and chief executive officer commented, "Lloyd has excellent business experience in sales, marketing and corporate development. Lloyd brings with him a strong background in evaluating product opportunities and developing marketing alliances."

Glenn comes to Atrix with 20 years experience in the areas of pharmaceutical marketing, product and corporate development. Glenn began his career as a product manager at Allergan where he was responsible for the launch of Botox (Botulinum Toxin Type-A) as well as developing strategic plans moving Allergan into neurology and other business areas. He has also held several positions with Elan Pharmaceuticals, where he was ultimately the vice president of marketing, launching new products as well as managing several of Elan's strategic relationships. Glenn's most recent position was vice president of sales and marketing at Cell Pathways where he developed strategic marketing plans and forecasts for in-house development products. Glenn has a BS in marketing from Brigham Young University in Provo, Utah.